2016
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment
Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM. Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunology Research 2016, 4: 179-182. PMID: 26701266, PMCID: PMC4881844, DOI: 10.1158/2326-6066.cir-15-0160.Peer-Reviewed Original ResearchConceptsCentral nervous systemBrain metastasesActive brain lesionsNew immunomodulating agentsImmune checkpoint inhibitorsRole of immunotherapyPembrolizumab treatmentCheckpoint inhibitorsCNS lesionsReactive astrocytosisImmune suppressionPerilesional edemaInflammatory cellsMicroglial cellsImmunomodulating agentMental statusBrain lesionsHistologic evaluationMost trialsNervous systemCentral enhancementTumor cellsPatientsMetastasisLesions
2000
Toward more rational prediction of outcome in patients with high-grade subarachnoid hemorrhage.
Chiang V, Claus E, Awad I. Toward more rational prediction of outcome in patients with high-grade subarachnoid hemorrhage. Neurosurgery 2000, 46: 28-35; discussion 35-6. PMID: 10626932, DOI: 10.1097/00006123-200001000-00006.Peer-Reviewed Original ResearchConceptsGlasgow Coma ScaleHigh-grade subarachnoid hemorrhageWorse clinical gradeSubarachnoid hemorrhageHess scaleOutcome predictionWFNS scaleMultivariate analysisPoor outcome groupGlasgow Outcome ScaleClinical grading scaleNeurological Surgeons (WFNS) scalePretreatment gradeComa ScaleConsecutive patientsKarnofsky scalePoor outcomeSingle institutionAccurate outcome predictionClinical examinationOutcome ScaleFavorable outcomeMental statusOutcome groupClinical grade